{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:42:32Z","timestamp":1788982952574,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Centre Egypt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A set of 3,5-bis(ylidene)-4-piperidone-1-phosphonothioates\n                    <jats:bold>20a\u2012l<\/jats:bold>\n                    was synthesized in high yields through dehydrochlorination reaction of 3,5-bis(ylidene)-4-piperidones\n                    <jats:bold>18a\u2012l<\/jats:bold>\n                    and diethyl chlorothiophosphate\n                    <jats:bold>19<\/jats:bold>\n                    in DMF containing quantitative amounts of TEA at 0\u00a0\u00b0C. Most of the synthesized agents exhibit effective antiproliferation properties against a variety of cancer cell lines (MCF7\/breast, HCT116\/colon, and A431\/skin), outperforming the efficacy of the clinically approved drugs. Compound\n                    <jats:bold>20c<\/jats:bold>\n                    (R\u00a0=\u20093-ClC\n                    <jats:sub>6<\/jats:sub>\n                    H\n                    <jats:sub>4<\/jats:sub>\n                    ) is the most effective analog discovered with a sub-micromolar activity against MCF7 (IC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u20090.650, 3.15 and 3.97 \u00b5M, for\n                    <jats:bold>20c<\/jats:bold>\n                    , 5-fluorouracil, and sunitinib, respectively) as well as remarkable efficacy against HCT116, and A431 (IC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u20091.445 and 2.920 \u00b5M respectively for\n                    <jats:bold>20c<\/jats:bold>\n                    , compared to 20.43 and 23.44 \u00b5M respectively for 5-fluorouracil). The synthesized analogs demonstrating considerable anti-MCF7 properties were evaluated for their biochemical properties against MDM2, p53, and topoisomerase I\/II. Compound\n                    <jats:bold>20k<\/jats:bold>\n                    [R\u00a0=\u20093,4,5-(MeO)\n                    <jats:sub>3<\/jats:sub>\n                    C\n                    <jats:sub>6<\/jats:sub>\n                    H\n                    <jats:sub>2<\/jats:sub>\n                    ] is the most effective anti-MDM2 agent with a potency higher than the standard reference (% inhibition of 65.3, for\n                    <jats:bold>20k<\/jats:bold>\n                    , and 42.2 for doxorubicin; i.e. 1.55-fold). Biochemical activation of p53 by the synthesized analogs is consistent with the anti-MDM2 properties. Compound\n                    <jats:bold>20i<\/jats:bold>\n                    (R\u00a0=\u20094-MeOC\n                    <jats:sub>6<\/jats:sub>\n                    H\n                    <jats:sub>4<\/jats:sub>\n                    ) is the most effective topo-I and topo-II\u03b1 inhibitor with potency close to that of the standard references (Dxd, and etoposide). Some of the synthesized agents showed selectivity for topo-II\u03b1 over topo-I. Molecular docking results (PDB: 4OAS) are consistent with the observed properties against MDM2. Based on the biological and biochemical findings, some of the synthesized compounds could serve as promising multi-targeted inhibitors.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-25796-6","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T10:53:22Z","timestamp":1763463202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antineoplastic 4-piperidone-1-phosphonothioates with potential multi-targeted inhibitory properties"],"prefix":"10.1038","volume":"15","author":[{"given":"Mohamed S.","family":"Bekheit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva S.","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benson M","family":"Kariuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A. F.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanaa","family":"Farag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel S.","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"25796_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.cbpa.2020.05.009","volume":"57","author":"AR de Lera","year":"2020","unstructured":"de Lera, A. R. & Ganesan, A. Two-hit wonders: the expanding universe of multitargeting epigenetic agents. Curr. Opin. Chem. Biol. 57, 135\u2013154. https:\/\/doi.org\/10.1016\/j.cbpa.2020.05.009 (2020).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"25796_CR2","doi-asserted-by":"publisher","first-page":"113260","DOI":"10.1016\/j.ejmech.2021.113260","volume":"214","author":"E Lenci","year":"2021","unstructured":"Lenci, E. et al. Multitargeting application of proline-derived peptidomimetics addressing cancer-related human matrix metalloproteinase 9 and carbonic anhydrase II. Eur. J. Med. Chem. 214, 113260. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113260 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR3","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41598-024-82005-6","volume":"15","author":"DR Aboshouk","year":"2025","unstructured":"Aboshouk, D. R. et al. Design and synthesis of antiproliferative 2-oxoindolin-3-ylidenes incorporating Urea function with potential VEGFR-2 inhibitory properties. Sci. Rep. 15, 618. https:\/\/doi.org\/10.1038\/s41598-024-82005-6 (2025).","journal-title":"Sci. Rep."},{"key":"25796_CR4","doi-asserted-by":"publisher","first-page":"116626","DOI":"10.1016\/j.ejmech.2024.116626","volume":"275","author":"ZL Zang","year":"2024","unstructured":"Zang, Z. L., Wang, Y. X., Battini, N., Gao, W. W. & Zhou, C. H. Synthesis and antibacterial medicinal evaluation of Carbothioamido Hydrazonyl thiazolylquinolone with multitargeting antimicrobial potential to combat increasingly global resistance. Eur. J. Med. Chem. 275, 116626. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116626 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR5","doi-asserted-by":"publisher","first-page":"135693","DOI":"10.1016\/j.molstruc.2023.135693","volume":"1287","author":"KM Sakita","year":"2023","unstructured":"Sakita, K. M. et al. Structure-based drug design of multi-targeting inhibitors of human pathogen fungi. J. Mol. Struct. 1287, 135693. https:\/\/doi.org\/10.1016\/j.molstruc.2023.135693 (2023).","journal-title":"J. Mol. Struct."},{"key":"25796_CR6","doi-asserted-by":"publisher","first-page":"115152","DOI":"10.1016\/j.ejmech.2023.115152","volume":"249","author":"J Chauhan","year":"2023","unstructured":"Chauhan, J. et al. Development of indolealkylamine derivatives as potential multi-target agents for COVID-19 treatment. Eur. J. Med. Chem. 249, 115152. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115152 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR7","doi-asserted-by":"publisher","first-page":"115292","DOI":"10.1016\/j.ejmech.2023.115292","volume":"252","author":"MS Bekheit","year":"2023","unstructured":"Bekheit, M. S., Panda, S. S. & Girgis, A. S. Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2. Eur. J. Med. Chem. 252, 115292. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115292 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ejmech.2017.08.032","volume":"139","author":"R Xing","year":"2017","unstructured":"Xing, R. et al. Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted Inhibition of TS, garftase and AICARFTase. Eur. J. Med. Chem. 139, 531\u2013541. https:\/\/doi.org\/10.1016\/j.ejmech.2017.08.032 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","volume":"142","author":"GL Beretta","year":"2017","unstructured":"Beretta, G. L., Cassinelli, G., Pennati, M., Zuco, V. & Gatti, L. Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents. Eur. J. Med. Chem. 142, 271\u2013289. https:\/\/doi.org\/10.1016\/j.ejmech.2017.07.062 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR10","doi-asserted-by":"publisher","first-page":"114464","DOI":"10.1016\/j.ejmech.2022.114464","volume":"238","author":"Z Sang","year":"2022","unstructured":"Sang, Z., Wang, K., Dong, J. & Tang, L. Alzheimer\u2019s disease: updated multi-targets therapeutics are in clinical and in progress. Eur. J. Med. Chem. 238, 114464. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114464 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR11","doi-asserted-by":"publisher","first-page":"31102","DOI":"10.1039\/d2ra05518j","volume":"12","author":"AS Girgis","year":"2022","unstructured":"Girgis, A. S., D\u2019Arcy, P., Aboshouk, D. R. & Bekheit, M. S. Synthesis and bio-properties of 4-piperidone containing compounds as Curcumin mimics. RSC Adv. 12, 31102\u201331123. https:\/\/doi.org\/10.1039\/d2ra05518j (2022).","journal-title":"RSC Adv."},{"key":"25796_CR12","doi-asserted-by":"publisher","first-page":"15075","DOI":"10.1021\/acs.jmedchem.0c00812","volume":"63","author":"M Bazzaro","year":"2020","unstructured":"Bazzaro, M. & Linder, S. Dienone compounds: targets and Pharmacological responses. J. Med. Chem. 63, 15075\u201315093. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00812 (2020).","journal-title":"J. Med. Chem."},{"key":"25796_CR13","doi-asserted-by":"publisher","first-page":"112177","DOI":"10.1016\/j.ejmech.2020.112177","volume":"192","author":"J Moreira","year":"2020","unstructured":"Moreira, J., Saraiva, L., Pinto, M. M. & Cidade, H. Diarylpentanoids with antitumor activity: A critical review of structure-activity relationship studies. Eur. J. Med. Chem. 192, 112177. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112177 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejmech.2019.04.058","volume":"177","author":"FC Rodrigues","year":"2019","unstructured":"Rodrigues, F. C., Kumar, N. V. A. & Thakur, G. Developments in the anticancer activity of structurally modified curcumin: an up-to-date review. Eur. J. Med. Chem. 177, 76\u2013104. https:\/\/doi.org\/10.1016\/j.ejmech.2019.04.058 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1021\/acs.jmedchem.5b01706","volume":"59","author":"SS Karki","year":"2016","unstructured":"Karki, S. S. et al. 3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A novel class of potent tumor-selective cytotoxins. J. Med. Chem. 59, 763\u2013769. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01706 (2016).","journal-title":"J. Med. Chem."},{"key":"25796_CR16","doi-asserted-by":"publisher","first-page":"101280","DOI":"10.1016\/j.tranon.2021.101280","volume":"15","author":"J Koroth","year":"2022","unstructured":"Koroth, J. et al. Curcumin derivative 1, 2-bis [(3E, 5E)-3, 5-bis [(2-chlorophenyl) methylene]-4-oxo-1-piperidyl] ethane-1, 2-dione (ST03) induces mitochondria mediated apoptosis in ovarian cancer cells and inhibits tumor progression in EAC mouse model. Transl Oncol. 15, 101280. https:\/\/doi.org\/10.1016\/j.tranon.2021.101280 (2022).","journal-title":"Transl Oncol."},{"key":"25796_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s43440-021-00322-3","volume":"74","author":"L Contreras","year":"2022","unstructured":"Contreras, L. et al. Three novel Piperidones exhibit tumor\u2013selective cytotoxicity on leukemia cells via protein degradation and stress\u2013mediated mechanisms. Pharmacol. Rep. 74, 159\u2013174. https:\/\/doi.org\/10.1007\/s43440-021-00322-3 (2022).","journal-title":"Pharmacol. Rep."},{"key":"25796_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejmech.2016.05.041","volume":"121","author":"H Zhu","year":"2016","unstructured":"Zhu, H. et al. Synthesis and optimization of novel allylated mono-carbonyl analogs of Curcumin (MACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI) in rats. Eur. J. Med. Chem. 121, 181\u2013193. https:\/\/doi.org\/10.1016\/j.ejmech.2016.05.041 (2016).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR19","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1016\/j.ejmech.2011.03.060","volume":"46","author":"AM Katsori","year":"2011","unstructured":"Katsori, A. M. et al. Curcumin analogues as possible anti-proliferative & anti-inflammatory agents. Eur. J. Med. Chem. 46, 2722\u20132735. https:\/\/doi.org\/10.1016\/j.ejmech.2011.03.060 (2011).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ejmech.2014.06.034","volume":"83","author":"SNA Bukhari","year":"2014","unstructured":"Bukhari, S. N. A. et al. Synthesis of \u03b1, \u03b2-unsaturated carbonyl based compounds as acetylcholinesterase and butyrylcholinesterase inhibitors: Characterization, molecular modeling, QSAR studies and effect against amyloid \u03b2-induced cytotoxicity. Eur. J. Med. Chem. 83, 355\u2013365. https:\/\/doi.org\/10.1016\/j.ejmech.2014.06.034 (2014).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR21","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1016\/j.bmc.2016.04.015","volume":"24","author":"GF Zha","year":"2016","unstructured":"Zha, G. F. et al. A. Biological evaluation of synthetic \u03b1,\u03b2-unsaturated carbonyl based cyclohexanone derivatives as neuroprotective novel inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-\u03b2 aggregation. Bioorg. Med. Chem. 24, 2352\u20132359. https:\/\/doi.org\/10.1016\/j.bmc.2016.04.015 (2016).","journal-title":"Bioorg. Med. Chem."},{"key":"25796_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejmech.2017.05.016","volume":"136","author":"R Fu","year":"2017","unstructured":"Fu, R., Sun, Y. & Sheng, W. Liao, D.-f. Designing multi-targeted agents: an emerging anticancer drug discovery paradigm. Eur. J. Med. Chem. 136, 195\u2013211. https:\/\/doi.org\/10.1016\/j.ejmech.2017.05.016 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR23","doi-asserted-by":"publisher","first-page":"105466","DOI":"10.1016\/j.bioorg.2021.105466","volume":"117","author":"AM Srour","year":"2021","unstructured":"Srour, A. M. et al. Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties. Bioorg. Chem. 117, 105466. https:\/\/doi.org\/10.1016\/j.bioorg.2021.105466 (2021).","journal-title":"Bioorg. Chem."},{"key":"25796_CR24","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/ph18020274","volume":"18","author":"AS Girgis","year":"2025","unstructured":"Girgis, A. S. et al. The therapeutic potential of spirooxindoles in cancer: A focus on p53\u2013MDM2 modulation. Pharmaceuticals 18, 274. https:\/\/doi.org\/10.3390\/ph18020274 (2025).","journal-title":"Pharmaceuticals"},{"key":"25796_CR25","doi-asserted-by":"publisher","first-page":"114334","DOI":"10.1016\/j.ejmech.2022.114334","volume":"236","author":"S Wang","year":"2022","unstructured":"Wang, S. & Chen, F. E. Small-molecule MDM2 inhibitors in clinical trials for cancer therapy. Eur. J. Med. Chem. 236, 114334. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114334 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR26","doi-asserted-by":"publisher","unstructured":"Sun, D. et al. Medina, J. C. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J. Med. Chem. 57, 1454\u20131472. (2014). https:\/\/doi.org\/10.1021\/jm401753e","DOI":"10.1021\/jm401753e"},{"key":"25796_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/13543776.2019.1582645","volume":"29","author":"L Skalniak","year":"2019","unstructured":"Skalniak, L., Surmiak, E. & Holak, T. A. A therapeutic patent overview of MDM2\/X-targeted therapies (2014\u20132018). Expert Opin. Ther. Pat. 29, 151\u2013170. https:\/\/doi.org\/10.1080\/13543776.2019.1582645 (2019).","journal-title":"Expert Opin. Ther. Pat."},{"key":"25796_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2018.09.044","volume":"159","author":"G Liao","year":"2018","unstructured":"Liao, G. et al. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy. Eur. J. Med. Chem. 159, 1\u20139. https:\/\/doi.org\/10.1016\/j.ejmech.2018.09.044 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR29","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.1021\/jm300354j","volume":"14","author":"Y Rew","year":"2012","unstructured":"Rew, Y. et al. Structure-based design of novel inhibitors of the MDM2\u2013p53 interaction. J. Med. Chem. 14, 4936\u20134954. https:\/\/doi.org\/10.1021\/jm300354j (2012).","journal-title":"J. Med. Chem."},{"key":"25796_CR30","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41419-018-0825-1","volume":"9","author":"NG Her","year":"2018","unstructured":"Her, N. G. et al. Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells. Cell. Death Dis. 9, 792. https:\/\/doi.org\/10.1038\/s41419-018-0825-1 (2018).","journal-title":"Cell. Death Dis."},{"key":"25796_CR31","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1016\/j.bmcl.2014.06.073","volume":"24","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein\u2013protein interaction. Bioorg. Med. Chem. Lett. 24, 3782\u20133785. https:\/\/doi.org\/10.1016\/j.bmcl.2014.06.073 (2014).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"25796_CR32","doi-asserted-by":"publisher","first-page":"28609","DOI":"10.1074\/jbc.M703796200","volume":"282","author":"K Selvendiran","year":"2007","unstructured":"Selvendiran, K. et al. EF24 induces G2\/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J. Biol. Chem. 282, 28609\u201328618. https:\/\/doi.org\/10.1074\/jbc.M703796200 (2007).","journal-title":"J. Biol. Chem."},{"key":"25796_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejmech.2018.02.065","volume":"150","author":"S Dadashpour","year":"2018","unstructured":"Dadashpour, S. & Emami, S. Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms. Eur. J. Med. Chem. 150, 9\u201329. https:\/\/doi.org\/10.1016\/j.ejmech.2018.02.065 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR34","doi-asserted-by":"publisher","unstructured":"Zhang, H. et al. Not only the top: type I topoisomerases function in multiple tissues and organs development in plants. J Adv. Res https:\/\/doi.org\/10.1016\/j.jare.2024.12.011(inpress).","DOI":"10.1016\/j.jare.2024.12.011(inpress)"},{"key":"25796_CR35","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","volume":"17","author":"Y Pommier","year":"2010","unstructured":"Pommier, Y., Leo, E., Zhang, H. & Marchand, C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 17, 421\u2013433. https:\/\/doi.org\/10.1016\/j.chembiol.2010.04.012 (2010).","journal-title":"Chem. Biol."},{"key":"25796_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ejmech.2016.09.023","volume":"125","author":"J Akhtar","year":"2017","unstructured":"Akhtar, J., Khan, A. A., Ali, Z., Haider, R. & Yar, M. S. Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities. Eur. J. Med. Chem. 125, 143\u2013189. https:\/\/doi.org\/10.1016\/j.ejmech.2016.09.023 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR37","unstructured":"Irinotecan accessed on Jun. 19, : Uses, Interactions, Mechanism of Action.  https:\/\/go.drugbank.com\/drugs\/DB00762 (2025)."},{"key":"25796_CR38","unstructured":"Topotecan accessed on Jun. 19, : Uses, Interactions, Mechanism of Action https:\/\/go.drugbank.com\/drugs\/DB01030 (2025)."},{"key":"25796_CR39","unstructured":"Keytruda accessed on Jun. 19, : Uses, Dosage, Side Effects, Warnings.  https:\/\/www.drugs.com\/history\/keytruda.html (2025)."},{"key":"25796_CR40","unstructured":"Camptothecin https:\/\/go.drugbank.com\/drugs\/DB04690 (2025). (accessed on Jun. 19."},{"key":"25796_CR41","unstructured":"Etoposide accessed on Jun. 19, : Uses, Interactions, Mechanism of Action. https:\/\/go.drugbank.com\/drugs\/DB00773 (2025)."},{"key":"25796_CR42","unstructured":"Etoposide Uses, S., Effects & Warnings https:\/\/www.drugs.com\/mtm\/etoposide.html (2025). accessed on Jun. 19."},{"key":"25796_CR43","unstructured":"Doxorubicin accessed on Jun. 19, : Uses, Interactions, Mechanism of Action. https:\/\/go.drugbank.com\/drugs\/DB00997 (2025)."},{"key":"25796_CR44","unstructured":"Doxorubicin Uses, S., Effects & Warnings https:\/\/www.drugs.com\/mtm\/doxorubicin.html (2025). (accessed on Jun. 19."},{"key":"25796_CR45","unstructured":"Epirubicin https:\/\/go.drugbank.com\/drugs\/DB00445 (2025). (accessed on Jun. 19."},{"key":"25796_CR46","unstructured":"Epirubicin Uses, S., Effects & Warnings https:\/\/www.drugs.com\/mtm\/epirubicin.html (2025). accessed on Jun. 19."},{"key":"25796_CR47","doi-asserted-by":"publisher","unstructured":"Jha, A. et al. Curcumin-inspired cytotoxic 3,5-bis(arylmethylene)-1-(N-(ortho-substituted aryl)maleamoyl)-4-piperidones: a novel group of topoisomerase II alpha inhibitors. Bioorg Med. Chem 23, 6404\u20136417 https:\/\/doi.org\/10.1016\/j.bmc.2015.08.023(2015).","DOI":"10.1016\/j.bmc.2015.08.023(2015"},{"key":"25796_CR48","doi-asserted-by":"publisher","first-page":"e202201406","DOI":"10.1002\/slct.202201406","volume":"7","author":"MA Youssef","year":"2022","unstructured":"Youssef, M. A. et al. Novel Curcumin mimics: Design, synthesis, biological properties and computational studies of piperidone-piperazine conjugates. ChemistrySelect 7, e202201406. https:\/\/doi.org\/10.1002\/slct.202201406 (2022).","journal-title":"ChemistrySelect"},{"key":"25796_CR49","doi-asserted-by":"publisher","first-page":"33761","DOI":"10.1039\/c9ra05661k","volume":"9","author":"NG Fawzy","year":"2019","unstructured":"Fawzy, N. G. et al. Synthesis, human topoisomerase II\u03b1 inhibitory properties and molecular modeling studies of antiproliferative Curcumin mimics. RSC Adv. 9, 33761\u201333774. https:\/\/doi.org\/10.1039\/c9ra05661k (2019).","journal-title":"RSC Adv."},{"key":"25796_CR50","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2174\/1871520619666190408131639","volume":"19","author":"NG Fawzy","year":"2019","unstructured":"Fawzy, N. G. et al. Novel Curcumin inspired antineoplastic 1-sulfonyl-4-piperidones: Design, synthesis and molecular modeling studies. Anti-Cancer Agents Med. Chem. 19, 1069\u20131078. https:\/\/doi.org\/10.2174\/1871520619666190408131639 (2019).","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"25796_CR51","doi-asserted-by":"publisher","first-page":"o1299","DOI":"10.1107\/S1600536811015984","volume":"67","author":"Y Kia","year":"2011","unstructured":"Kia, Y., Osman, H., Murugaiyah, V., Hemamalini, M. & Fun, H. K. (3E,5E)-3,5-Dibenzylidene-1-[3-(piperidin-1-yl)propanoyl]piperidin-4-one. Acta Crystallog Sect. E. 67, o1299\u2013o1300. https:\/\/doi.org\/10.1107\/S1600536811015984 (2011).","journal-title":"Acta Crystallog Sect. E"},{"key":"25796_CR52","doi-asserted-by":"publisher","first-page":"13880","DOI":"10.1038\/s41598-022-17883-9","volume":"12","author":"NG Fawazy","year":"2022","unstructured":"Fawazy, N. G. et al. Development of spiro-3-indolin-2-one containing compounds of antiproliferative and anti-SARS-CoV-2 properties. Sci. Rep. 12, 13880. https:\/\/doi.org\/10.1038\/s41598-022-17883-9 (2022).","journal-title":"Sci. Rep."},{"key":"25796_CR53","unstructured":"Fluorouracil Injection - NCI - National Cancer Institute. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/fluorouracil (2025). accessed on Jun. 19."},{"key":"25796_CR54","unstructured":"Fluorouracil (Topical) - NCI - National Cancer Institute. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/fluorouracil-topical (2025). accessed on Jun. 19."},{"key":"25796_CR55","unstructured":"Sutent (sunitinib malate) FDA Approval History. https:\/\/www.drugs.com\/history\/sutent.html (2025). accessed on Jun. 19."},{"key":"25796_CR56","unstructured":"Sunitinib Malate - NCI - National Cancer Institute. accessed on Jun. 10, (2025). https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/sunitinibmalate (accessed on Jun. 19, 2025)."},{"key":"25796_CR57","unstructured":"Human MDM2 (Mdm2 p53 Binding. Protein Homolog) ELISA Kit, Cat: ELK4557, ELK Biotechnology. http:\/\/www.elkbiotech.com"},{"key":"25796_CR58","unstructured":"Human, T. P. (Tumor Protein p53) ELISA Kit, Cat: ELK1507, ELK Biotechnology. http:\/\/www.elkbiotech.com"},{"key":"25796_CR59","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1016\/j.bmcl.2016.08.082","volume":"26","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y. et al. Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology. Bioorg. Med. Chem. Lett. 26, 5069\u20135072. https:\/\/doi.org\/10.1016\/j.bmcl.2016.08.082 (2016).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"25796_CR60","unstructured":"Human, T. O. P. (Topoisomerase I) ELISA Kit, Cat: ELK3045. http:\/\/www.elkbiotech.com"},{"key":"25796_CR61","unstructured":"Human, D. N. A. Topoisomerase 2-alpha, TOP2A ELISA Kit, Cat: E6652Hu, www.bt-laboratory.com (2025). accessed on Jun. 19."},{"key":"25796_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2011.11.034","volume":"50","author":"AS Girgis","year":"2012","unstructured":"Girgis, A. S., Tala, S. R., Oliferenko, P. V., Oliferenko, A. A. & Katritzky, A. R. Computer-assisted rational design, synthesis, and bioassay of nonsteroidal anti-inflammatory agents. Eur. J. Med. Chem. 50, 1\u20138. https:\/\/doi.org\/10.1016\/j.ejmech.2011.11.034 (2012).","journal-title":"Eur. J. Med. Chem."},{"key":"25796_CR63","unstructured":"Co-crystal structure. Of MDM2 (17\u2013111) in complex with compound 25, https:\/\/www.rcsb.org\/structure\/4OAS (2025). accessed on Jun. 19."},{"key":"25796_CR64","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1038\/s41598-025-85588-w","volume":"15","author":"DR Aboshouk","year":"2025","unstructured":"Aboshouk, D. R. et al. Curcumin mimics of potential chemoprevention with NQO1 induction properties. Sci. Rep. 15, 2332. https:\/\/doi.org\/10.1038\/s41598-025-85588-w (2025).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25796-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25796-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25796-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T23:03:45Z","timestamp":1763507025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25796-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25796"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25796-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"27 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of competing interest"}}],"article-number":"40363"}}